About this episode

Bihua Chen discusses evaluating science and risk in biotech investing.

Bihua, CEO and PM of Cormorant Asset Management ($2.5B AUM), explains how she evaluates science, risk, and opportunity across both public and private biotech markets. She shares how investors can separate signal from hype, underwrite uncertainty in drug development, and identify the breakthroughs most likely to shape the future of medicine. - This podcast/webcast is provided for informational purposes only and should not be considered legal, tax, investment, or business advice. It is not a solicitation, recommendation, or endorsement. All opinions expressed by participants are their own and do not necessarily reflect the views of the Evoke Advisors Division of MAI Capital Management, LLC ("Evoke”), its affiliates, or any companies mentioned. Information shared has not been independently verified by MAI or its affiliates. MAI Capital Management, LLC (“MAI”) is registered with the U.S. Securities and Exchange Commission ("SEC"), which does not imply any particular level of skill or training. Certain information contained herein has been obtained from third party sources and such information has not been independently verified. No representation, warranty, or undertaking, expressed…

Topics covered

• biotech investing
• drug development
• investment strategies
• risk evaluation
• medical breakthroughs

More episodes of Insightful Investor

• #132 - Steven Klinsky: Private Markets as Operational Edge · July 21, 2026 · 37 min
• #131 - Jason Schwarz: Scaling Institutional Private Markets · July 14, 2026 · 46 min
• #129 - Cathy Marcus: Real Estate Reset · June 30, 2026 · 54 min
• #128 - Sarah Ketterer: Temporary Setbacks, Durable Businesses · June 23, 2026 · 57 min
• #127 - Brian D'Arcy: Institutional Sports Investing · June 16, 2026 · 55 min

Explore listener stats, chart rankings, contacts and more on the Insightful Investor podcast page.